Otonomy is a biopharmaceutical company focused on the development of innovative therapeutics for neurotology. Co. developed the application of drug delivery technology to the ear. Co.'s primary focus is on the development of three programs in its pipeline: OTO-313 in Phase 2 for tinnitus; OTO-413 in Phase 2a for hearing loss; and OTO-825, a gene therapy for congenital hearing loss, in investigational new drug (IND)-enabling activities. Additionally, Co. is conducting preclinical development of OTO-510 for otoprotection and OTO-6XX for severe hearing loss. The OTIC stock yearly return is shown above.
The yearly return on the OTIC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OTIC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|